Synopsis: A key international expansion initiative is moving closer to completion as Viyash Scientific takes another step to strengthen its global animal healthcare platform. The latest development reflects the company’s strategy of expanding through acquisitions in regulated overseas markets, potentially creating new growth opportunities while reinforcing its long-term international presence. Here’s what the definitive agreement means and why the transaction is strategically significant.
Recently, the global animal healthcare industry has seen a steady wave of consolidation as companies expand geographically, strengthen manufacturing, and diversify product portfolios. Acquisitions are preferred for entering regulated markets, where starting from scratch can take time, money, and approvals. Given this, Viyash Scientific has taken another important step in expanding its European animal healthcare business.
Shares of Viyash Scientific Limited were trading at Rs 259.5, down by 2.13 percent from the previous close of Rs 265.15. The stock opened at Rs 266 and struck an intraday high of Rs 266.65, and the day’s low is Rs 255.55. The company currently has a market capitalisation of Rs 11,271 crore.
Viyash Signs Definitive Agreement to Acquire BioForLife Italia
Viyash Scientific Limited informed the stock exchanges that its step-down wholly owned subsidiary, Alivira Animal Health Limited, Ireland, has executed a Sale and Purchase Agreement (SPA) with the shareholders of BioForLife Italia S.r.l., Milan, Italy, to acquire 100% of the company’s issued and outstanding share capital.
The acquisition will be completed for a base consideration of approximately €16.976 million (around ₹186.7 crore). Under the agreed structure, €15 million (around ₹165 crore) will be paid at closing, while approximately €1.976 million (around ₹21.7 crore) will be retained as deferred consideration.
The company further stated that the deferred consideration mechanism has been revised and is now linked to specified contractual continuation conditions under the Sale and Purchase Agreement. Apart from this revision, all other material terms disclosed in the company’s earlier announcement remain unchanged.
The transaction is yet to be completed and remains subject to obtaining the applicable Italian Foreign Direct Investment (FDI) / Golden Power clearance, as well as the fulfilment or waiver of other customary closing conditions specified in the agreement.
Acquisition Strengthens European Animal Healthcare Platform
The acquisition represents another strategic step in expanding Alivira Animal Health’s international presence, particularly across regulated European markets. Europe is one of the world’s largest veterinary pharmaceutical markets, supported by stringent quality standards, well-established distribution networks, and rising demand for livestock as well as companion animal healthcare products.
Viyash Scientific can boost its commercial presence, customer relationships, and market access by acquiring a regional player without spending years building a business. The transaction supports the company’s goal of building a diversified global animal healthcare platform in developed markets.
Industry Consolidation Continues to Accelerate
The global animal healthcare sector continues to benefit from structural growth drivers, including increasing pet ownership, rising expenditure on animal health, improved livestock productivity, and greater focus on food safety and disease prevention.
These trends have encouraged pharmaceutical companies to pursue acquisitions that enhance manufacturing capabilities, broaden product portfolios, and improve access to regulated international markets. Rather than relying solely on organic expansion, companies are increasingly using strategic acquisitions to accelerate growth, achieve operational synergies, and strengthen competitive positioning.
Against this backdrop, Viyash Scientific’s acquisition of BioForLife Italia aligns with the broader industry trend of expanding through cross-border transactions to build scale in high-value veterinary healthcare markets.
Financial Highlights
The company delivered a robust operational performance in Q4 FY26, with revenue increasing 128.9% YoY to ₹920 crore from ₹402 crore in Q4 FY25. The strong topline growth was accompanied by improved operating efficiency, as operating profit surged 300% YoY to ₹184 crore from ₹46 crore, while the operating profit margin (OPM) expanded to 20% from 12%, reflecting better execution and operating leverage.
Profitability improved significantly during the quarter. Profit Before Tax (PBT) jumped 681% YoY to ₹125 crore from ₹16 crore, while net profit rose 560% YoY to ₹66 crore from ₹10 crore. Consequently, earnings per share (EPS) increased to ₹1.19 in Q4 FY26 from ₹0.37 in Q4 FY25, registering a 221.6% YoY growth, highlighting a sharp improvement in earnings generation.
The company maintains a healthy financial position with ROCE of 13.4%, ROE of 7.39%, and a debt-to-equity ratio of just 0.17, indicating a conservatively leveraged balance sheet. It also reported cash & cash equivalents of ₹270 crore, working capital of ₹1,309 crore, and a current ratio of 2.38, providing adequate liquidity to support future growth.
The long-term growth profile remains encouraging. Over the last five years, the company has delivered a sales CAGR of 20% and a profit CAGR of 15%. Growth has accelerated over the last three years, with sales CAGR of 34% and an impressive profit CAGR of 73%, reflecting sustained business expansion and improving profitability.
Insight and Industry Analysis
The acquisition of Viyash Scientific is part of a wider consolidation trend in the global animal health sector, where companies are increasingly growing through acquisitions to improve product portfolios, manufacturing capabilities and access to regulated international markets. Europe is still one of the most attractive regions, partly due to the high quality standards and the established veterinary pharmaceutical ecosystem.
Strategically, the acquisition provides Viyash Scientific with an opportunity to enhance its European footprint via Alivira Animal Health without the need to establish operations from the ground up. Investors are expected to continue to watch for regulatory approvals, the successful integration of BioForLife Italia and the company’s ability to generate operational synergies and grow its international revenue base in the future.
Viyash Scientific Limited (formerly Sequent Scientific Limited) is a global animal healthcare company engaged in the development, manufacturing, and marketing of veterinary pharmaceutical formulations and active pharmaceutical ingredients (APIs). Through its subsidiary Alivira Animal Health, the company operates across multiple international markets, serving both livestock and healthcare segments for companion animals.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
